E-P Therapeutics Team

BARRY RESSLER (Chairman) has been a director of the Company since its founding in January 2001. Mr. Ressler is also the Chief Executive Officer and Chairman of the Board of Triton Thalassic Technologies, Inc. (T 3I), a company engaged in the non-chemical pathogen inactivation of blood products; photo-activation of therapeutic compounds and the treatment and control of micro-organism contaminated fluids for the paper, automotive, food packaging and pharmaceutical industries. Mr. Ressler is also the President of STAR Associates, Inc., a company engaged in the consultation, strategic planning and project funding of early stage industrial process and therapeutic/diagnostic technologies.

From 1983 to December 1993 he served as Chief Executive Officer and Chairman of the Board of Universal Voltronics Corporation (UVC), a public company that developed high-voltage Pulse Power products for scientific research, defense, medical and industrial applications. In March 1990, UVC became a public subsidiary of Thermo Electron Corp.

Mr. Ressler is a co-inventor of patented high power ultraviolet radiation light sources and for monochromatic fluid treatment systems (blood products, packaged pharmaceuticals, ophthalmic therapy and food/beverage products).

THOMAS T. CHEN (Chief Scientist) received his Ph.D. degree in Genetics from the University of Alberta, Canada, in 1973.  He has served as a post-doctoral fellow at Queen’s University, Canada, Assistant and Professor at McMaster University, Canada and professor at the University of Maryland Biotechnology Institute and University of Connecticut.  From 1986-1995, Dr. Chen also served as Associate Director for research and faculty development at the Center of Marine Biotechnology, UMBI and Associate Provost of UMBI.  In 1995, Professor Chen was recruited by the University of Connecticut to head the Biotechnology Center and also serve as a professor at the Department of Molecular and Cell Biology.  He stepped down from the directorship of the Biotechnology Center in July 2002 and continues to serve as a professor in the Department of Molecular & Cell Biology.

During the past 30 years, Professor Chen has made numerous important contributions in the areas of molecular endocrinology and biotechnology and has recruited in excess of 10 million dollars of research funding to support his scientific pursuits.  He has published more than 138 scientific papers in peer-reviewed international journals.  In addition, he also holds three patents including the E-P technology.

STEVEN DIAMOND (Senior VP Chief Medical Officer-Operations) received his DO from Mid-Western University. He did his residency in pathology at the University of Wisconsin, Philadelphia Naval Hospital and Thomas Jefferson University. He is Board Certified in Anatomic and Clinical Pathology and is also Board Certified in Hematopathology. Dr. Diamond is currently Director of Esoterix, a national clinical trial laboratory. He is also Director of Laboratories at Hunterdon Medical Center in Flemington, NJ and is also the Medical Examiner of Hunterton County, NJ. Dr. Diamond is affiliated with Fox Chase Cancer Center through the Tumor Registry at his hospital.  Dr. Diamond received his MBA from the Wharton School of Business at the University of Pennsylvania and has received grants from the State of Pennsylvania for his medical information company.  He is currently on the Management Resource Committee of the College of American Pathologists and is a member of the American Society of Clinical Pathologists, American Board of Medicolegal Death Investigators and the Medical Society of Pennsylvania.